{"id":98014,"date":"2020-07-18T12:01:17","date_gmt":"2020-07-18T12:01:17","guid":{"rendered":"https:\/\/www.edristi.in\/?p=98014"},"modified":"2020-07-18T12:01:23","modified_gmt":"2020-07-18T12:01:23","slug":"itolizumab-receives-dcgi-nod","status":"publish","type":"post","link":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/itolizumab-receives-dcgi-nod\/","title":{"rendered":"Itolizumab Receives DCGI Nod"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Question: Consider the following statements:<br>(1) Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.<br>(2) Itolizumab is repurposed form of ALZUMAb launched in India in 2013 for treating chronic plaque psoriasis.<br>Of the above correct statement\/s is\/are:<\/strong><br>(a) Only 1<br>(b) Only 2<br>(c) Both 1&amp;2<br>(d) None of the above<br><strong>Answer: (c)<br>Related facts:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Drugs Controller General of India\u2019s (DCGI) has given market approval to the Itolizumab Injection.<\/li><li>The medicine will be used for the treatment of \u2018cytokine\u2019 release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.<\/li><li>Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.<\/li><li>It will be manufactured and formulated as an intravenous injection at Biocon\u2019s bio-manufacturing facility at Biocon Park, Bengaluru.<\/li><li>Itolizumab is repurposed form of ALZUMAb launched in India in 2013 for treating chronic plaque psoriasis.<\/li><li>Clinical trial of the Itolizumab was conducted at multiple hospitals in Mumbai and New Delhi.<\/li><\/ul>\n\n\n\n<p class=\"has-text-align-right wp-block-paragraph\"><strong>By-Amar Mani Upadhyay<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Links:<\/strong><br><a href=\"https:\/\/www.biocon.com\/biocon_press_release_20200711.asp\" target=\"_blank\" aria-label=\"undefined (opens in a new tab)\" rel=\"noreferrer noopener\">https:\/\/www.biocon.com\/biocon_press_release_20200711.asp<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Question: Consider the following statements:(1) Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.(2) Itolizumab is repurposed form of ALZUMAb launched in India in 2013 for treating chronic plaque psoriasis.Of the above correct statement\/s is\/are:(a) Only 1(b) Only 2(c) Both 1&amp;2(d) [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":98015,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1123],"tags":[3067],"class_list":["post-98014","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snes","tag-scientific"],"_links":{"self":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/98014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/comments?post=98014"}],"version-history":[{"count":0,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/98014\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media\/98015"}],"wp:attachment":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media?parent=98014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/categories?post=98014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/tags?post=98014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}